NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Partnerships for Health, Wealth and Innovation > Patient involvement partnership sets priorities for rare inherited anaemias

Patient involvement partnership sets priorities for rare inherited anaemias

28 February 2019 · Listed under Haematology and Stem Cells, Oxford Blood Group, Partnerships for Health, Wealth and Innovation, Patient and Public Involvement and Engagement

On the occasion of Rare Diseases Day, marked every year on the last day of February, we are sharing this article about how patients, carers, clinicians and researchers are collaborating to decide key questions to shape future research into rare forms of anaemia.

Patients with anaemia lack red blood cells, or haemoglobin, which means that these cells cannot successfully carry oxygen from the lungs to other cells in the body. While some forms of anaemia are relatively common and well-understood, it can take years for patients with rare inherited anaemias to receive a precise diagnosis, if they get one at all. These conditions also have few treatments, because of limited research funding.

A unique partnership

Since 2016, a group of patients from all over the UK with a range of rare anaemias, along with their carers have come together in person – or virtually – to work with researchers and clinicians to identify what should be the research priorities for those investigating these rare anaemias, so that their research makes a real difference to patients’ lives.

The research agenda has traditionally been set by scientists, clinicians, funding bodies and pharmaceutical companies, but this process excludes patients, who are the group most directly affected by the disease.

Patients also have personal insight into the condition, and can help refine the focus of research, for example by highlighting symptoms that particularly limit their everyday lives.

To ensure that the various players were consulted, a steering group was created that included researchers of the MRC Molecular Haematology Unit (MRC MHU) at the MRC Weatherall Institute of Molecular Medicine, as well as clinicians, patients and patient support groups representatives.

The team used the well-established structured format of the James Lind Alliance Priority Setting Partnership, previously used to produce 67 patient-driven research priorities in other conditions, to ensure that patients and carers had an equal voice in the discussion.

The aim of the project was to stimulate research on rare inherited anaemias by finding out what all partners believed to be the most important areas for future research, including in the areas of diagnosis, treatment and management of these conditions.

Transformational process

The project was led by Dr Noemi Roy, a postdoctoral researcher at the MRC MHU and Honorary Senior Clinical Lecturer supported by the NIHR Oxford BRC.

It included surveys, workshops and discussions. Patients, carers and healthcare professionals were on an equal footing in the discussions, and their diverse skills and points of view were complementary, including medical knowledge, patient perspectives and an understanding of the research landscape and NHS organisational issues.

“The process was transformational,” Dr Roy said. “As we worked together for two years, we got to know each other well, and we learned to adapt the language we use, the assumptions we make, and the different outcomes each of us were considering for the future.”

The process culminated in a final workshop with 34 participants, where consensus on key issues emerged and yielded a final list of ten research questions, covering the need for new treatment options, better quality of life and the need for information and samples to be shared. The final report was published last June and can be accessed here.

A future for inherited rare anaemias

The participants now hope that the areas identified by their diverse group will inform future research, helping both the funding charities that award research grants, and the researchers, in their choice of research question.

The partnership also made clear how important open, equal dialogue between all stakeholders was.

One patient said: “I can help future generations and raise the profile of rare anaemias. This work makes me feel like I have a part to play and that even though you’ve got a rare condition, you can still make a difference.”

← Blog looks at Oxford BRC Health Impact symposium
Event explores social challenges of personalised medicine →

News

  • Study highlights ongoing COVID-19 risk in some cancer patients despite vaccination 24 May 2022
  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre